Related Experiment Video
Updated: Apr 8, 2026
Electromechanical Assessment of Optogenetically Modulated Cardiomyocyte Activity
Published on: March 5, 2020
Quantitative Assessment of Ferroptosis in Cardiomyocytes Using Robust and Reliable Electrophysiological Biosensing
Shushan Hua1,2, Shoufang Tong2,3, Yuli Hu4
1Laboratory Medicine Center, Allergy Center, Department of Transfusion Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou 310014, China.
Insights
Researchers developed a novel biosensing platform to monitor ferroptosis (iron-dependent cell death) in heart cells. This technology allows for continuous, non-invasive tracking of ferroptosis progression, aiding in understanding cardiac disease and drug development.
Area of Science:
- Biomedical Engineering
- Cardiovascular Research
- Cell Death Mechanisms
Background:
- Ferroptosis, an iron-dependent cell death, is implicated in cardiovascular diseases due to cardiomyocyte damage from iron overload and lipid peroxidation.
- Current methods for monitoring ferroptosis are often invasive and lack dynamic, continuous tracking capabilities.
- Effective monitoring is crucial for understanding cardiac pathogenesis and developing targeted therapies.
Purpose of the Study:
- To develop a novel biosensing platform for non-invasive, label-free, and quantitative monitoring of cardiomyocyte ferroptosis.
- To validate the platform's ability to detect electrophysiological signatures associated with ferroptosis.
- To assess the platform's utility in drug screening and studying ferroptosis-related cardiac conditions.
Main Methods:
- Development of a custom 32-channel microelectrode array biosensing platform.
- Non-invasive, label-free electrophysiological monitoring of cardiomyocyte ferroptosis.
- Induction of ferroptosis using Erastin and assessment of rescue effects with ferrostatin-1.
- Comparison of detected electrophysiological changes with traditional biochemical assays.
Main Results:
- The biosensing platform successfully captured dynamic, time- and drug-dependent electrophysiological alterations during Erastin-induced ferroptosis.
- Detected electrophysiological changes correlated well with traditional biochemical assays, accurately reflecting ferroptosis progression.
- The platform demonstrated high specificity, successfully recording the rescue effects of ferrostatin-1.
Conclusions:
- The developed biosensing platform enables the visualization and continuous tracking of cardiomyocyte ferroptosis through electrophysiological monitoring.
- This technology offers a powerful tool for investigating ferroptosis mechanisms in cardiovascular pathology.
- The platform shows promise for high-throughput drug screening and the study of ferroptosis-related cardiac diseases.
Abstract:
Ferroptosis is an iron-dependent form of regulated cell death driven by dysregulated iron metabolism and subsequent lipid peroxidation, which contributes significantly to cardiovascular pathogenesis. While maintaining iron homeostasis is crucial for cardiac function, excessive iron accumulation initiates ferroptotic cell death, leading to cardiomyocyte damage. However, conventional biological methods lack the ability to dynamically and continuously monitor this process. To overcome this limitation, we developed a new biosensing platform centered on a custom 32-channel microelectrode array, which is designed for the non-invasive, label-free, and quantitative detection of electrophysiological signatures characteristic of cardiomyocyte ferroptosis. Using this platform, we successfully captured the drug concentration- and time-dependent electrophysiological alterations during Erastin-induced ferroptosis. Importantly, these detected electrophysiological changes closely aligned with traditional biochemical assays, accurately reflecting the progression of cardiomyocyte ferroptosis. The platform further demonstrated high specificity by recording the rescue effects of ferrostatin-1. Overall, our findings establish the feasibility of visualizing cardiomyocyte ferroptosis through electrophysiological monitoring, enabling continuous tracking of the entire process. This integrated biosensing system provides not only a powerful tool for investigating ferroptosis mechanisms but also a promising platform for drug screening and studying ferroptosis-related cardiac pathologies.
